Experimental Manipulation of Sleep and Circadian Rhythms and the Role Played on Reward Function in Teens
NCT ID: NCT04792697
Last Updated: 2025-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
100 participants
INTERVENTIONAL
2021-05-01
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Late sleep timing, short sleep duration and circadian misalignment are associated with increased substance use in teenagers and young adults. The central hypothesis of the Center for Adolescent Reward, Rhythms and Sleep (CARRS) is that adolescent development acts on underlying sleep and circadian traits to modify homeostatic sleep drive, circadian phase, and circadian alignment, which in turn impact cortico-limbic functions critical to SU risk (e.g., reward and cognitive control). Investigators further hypothesize that specific manipulations of sleep and circadian rhythms during adolescence will affect reward responsivity and cognitive control in either positive or negative directions. These manipulations will provide experimental support for our model, and proof of concept for novel clinical interventions to reduce the risk of SU and SUDs.
Most previous studies have examined individual components of circadian rhythms, sleep, and reward function in adolescence. Project 2 (P2) of CARRS will test an innovative and mechanistic model of brain circuitry that uses multi-method approaches, takes a developmental perspective, and incorporates key sleep and reward constructs. Most notably, P2 improves upon past observational work by testing an experimental intervention that manipulates sleep and circadian rhythms to directly examine its impact on reward function and cognitive control.
P2 will study 150 adolescents (age 13-15, 50% female) across two key sleep phenotypes: early sleep timing (low risk, n=50) and late sleep timing (high risk, n=100). All participants will complete the observational study: 2 weeks of home sleep monitoring (actigraphy \& sleep diary), followed by an overnight laboratory visit to assess self-report, behavioral, and neuroimaging (fMRI) tasks tapping cognitive control and reward function, as well as circadian phase via salivary melatonin and molecular rhythms via hair follicles. The Late group will continue to the experimental study, each participant randomized to manipulation or attentional control conditions (n=50 each). Investigators will probe whether advancing sleep/circadian timing and extending sleep duration via sleep scheduling and chronotherapeutic approaches (reducing PM light exposure; administering AM bright light) improves sleep, circadian, and neurobehavioral function relevant to SUD risk. Finally, repeated 6-month follow-up assessments of sleep and SU for all participants are included to examine longitudinal associations.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Advance/Extend Manipulation
For \~2 weeks, Manipulation participants will advance bedtime and regularize wake time. The first night of the manipulation will be conducted in the lab under tightly-controlled experimental conditions. Participants will then go home and for the next 12 days and will be instructed to:
* Sleep scheduling-- advance bedtime by 1.5 hours ( + sleep duration)
* Decrease evening blue light exposure via blue blocker goggles (2 hrs before bed)
* Increase morning bright light exposure via bright light goggles (30 min after rise)
* Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph
Increase morning bright light
Participants will wear Re-Timer bright glasses for 30 minutes each morning upon rising
Decrease evening blue light
Participants will wear tinted glasses that block blue wavelength light for 2 hours before bed
Sleep Scheduling
Participants will advance their bedtime by 1.5 hours and regularize their wake time
Monitor sleep, mood, and substance use
Participants will complete smartphone-based sleep, mood, and substance use monitoring
Control
Control participants will complete the baseline laboratory study, then maintain their habitual sleep schedules over the next 12 days at home, with no instruction on sleep timing or light exposure. Control participants will complete smartphone-and text-based assessments and wear an actigraphy watch to monitor their sleep, behavior and sleep habits thereby controlling for effort.
Monitor sleep, mood, and substance use
Participants will complete smartphone-based sleep, mood, and substance use monitoring
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Increase morning bright light
Participants will wear Re-Timer bright glasses for 30 minutes each morning upon rising
Decrease evening blue light
Participants will wear tinted glasses that block blue wavelength light for 2 hours before bed
Sleep Scheduling
Participants will advance their bedtime by 1.5 hours and regularize their wake time
Monitor sleep, mood, and substance use
Participants will complete smartphone-based sleep, mood, and substance use monitoring
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Physically and psychiatrically healthy
* Provision of written informed consent and assent
* Additional inclusion criterion for Experimental protocol: Meets operational definition of late sleep timing (\>10:50PM habitual bedtime)
Exclusion Criteria
* Significant or unstable acute or chronic medical conditions
* Frequent headaches or migraines
* History of seizures
* Current serious psychiatric disorder (e.g., depressive disorder, bipolar disorder, eating disorder, psychotic disorder diagnosis, alcohol use disorder or substance use disorder) that would interfere with completion of study procedures
* Current syndromal sleep disorders other than insomnia and delayed sleep phase disorder
* MRI contraindications (i.e., absence of metal in the body, claustrophobia)
* Medications that increase sensitivity to blue light/photosensitizing medications, including psychiatric neuroleptic drugs, psoralen drugs, antiarrhythmic drugs, etc.
* Changes to psychotropic medication regimen in the 2 weeks prior to enrollment, and/or major changes to medications during the study protocol
* If participants have an average bedtime that is later than 3:00AM or an average wake time later than 11:00AM they may be excluded from the study
* Participants should be EXCLUDED for other sleep disorders that require ongoing treatment
* Participants should be EXCLUDED for other sleep disorders that cause significant distress or impairment, per DSM 5 criteria in the Sleep SCID.
13 Years
15 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
University of Pittsburgh
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Brant Hasler
Associate Professor of Psychiatry, Psychology and Clinical and Translational Science
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brant Hasler, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Pittsburgh
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Western Psychiatric Hospital
Pittsburgh, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ronette G Blake, MS
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY20030271
Identifier Type: -
Identifier Source: org_study_id